The MDCK cells were seeded on a 96-well plate at the density of 1 × 104 cells/well. The Y30 extract (final 3.1–12.5%) was mixed with A/PR/8/34 or A/Aichi/2/68 viruses at a MOI of 0.1 in the infection medium and incubated for 30 min at 37°C in the presence of 5% CO2. Each mixture was added to the cells at 37°C in the presence of 5% CO2. The cells were treated with the Y30 extract (final 3.1–12.5%) for 24 h at 37°C in the presence of 5% CO2. Subsequently, the Y30-treated cells were washed prior to the addition of the A/PR/8/34 virus at a MOI of 0.1 in the infection medium. Water (final 3.1–12.5%) or bakuchiol (final 3.1–12.5 μM) were used as the negative or positive controls, respectively. After influenza A virus infection for 24 h, the cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 30 min at 4°C and subsequently permeabilized with 0.3% Triton X-100 for 20 min at 25°C. A mouse primary antibody was used to detect the NP of A/PR/8/34 or A/Aichi/2/68 viruses (FluA-NP 4F1; SouthernBiotech, AL, USA). An Alexa Fluor 488-conjugated goat anti-mouse IgG (H + L) antibody (Thermo Fisher Scientific) was used as the secondary antibody. Cell nuclei were then stained using diamidino-2-phenylindole (DAPI; Thermo Fisher Scientific). Wells were photographed using a fluorescence microscope (BIOREVO BZ-X700, Keyence, Osaka, Japan). The percentage of influenza A NP-positive cells per DAPI-positive cells were calculated based on measurements recorded using the BZ-X Analyzer software (Keyence).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.